|
Market Closed -
Nasdaq
00:30:00 24/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 4.910 USD | -7.71% |
|
-14.31% | -61.59% |
| 08-07 | Cytosorbents Corporation, Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-07 | Cytosorbents Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Cytosorbents Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 15.43 | - | - |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -61.57% | - | - |
| Enterprise Value (EV) | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 15.43 | 15.43 | 15.43 |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -61.57% | 0% | 0% |
| P/E | -7.35x | -2.07x | -1.73x | -2.39x | -4.92x | -1.12x | -5.46x | 8.18x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.1x | 0.1x | 0.1x | 0.1x | -0x | 0.1x | -0x |
| Capitalization / Revenue | 4.22x | 1.95x | 1.59x | 1.27x | 1.08x | 0.4x | 0.35x | 0.3x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.4x | 0.35x | 0.3x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -2.01x | -19.7x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -1.6x | -12.7x | 6.75x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -11.4 | -15 | -12.8 | -7.6 | -2.6 | -4.4 | -0.9 | 0.6 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 43.17 | 34.69 | 36.35 | 39.2 | 37.06 | 38.88 | 44.16 | 51.6 |
| EBITDA 1 | -15.81 | -26.84 | -26.05 | -11.46 | -13.3 | -7.667 | -0.7823 | - |
| EBIT 1 | -22.74 | -31.52 | -31.21 | -16.79 | -14.24 | -9.639 | -1.219 | 2.284 |
| Net income 1 | -24.56 | -32.81 | -28.51 | -20.72 | -8.198 | -13.91 | -2.772 | 2.284 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 83.800 | 31.000 | 22.200 | 18.200 | 12.784 | 4.910 | 4.910 | 4.910 |
| Nbr of stocks (in thousands) | 2,174 | 2,182 | 2,611 | 2,734 | 3,140 | 3,142 | - | - |
| Announcement Date | 08/03/22 | 09/03/23 | 14/03/24 | 31/03/25 | 25/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.12x | - | - | - | 15.43M | |
| 33.06x | 5.78x | 22.17x | 0.28% | 246B | |
| 37.37x | 6.7x | 21.23x | 0.64% | 156B | |
| 43.17x | 11.41x | 25.19x | -.--% | 141B | |
| 16.87x | 3.45x | 11.21x | -.--% | 64.66B | |
| 34.31x | 6.87x | 21.72x | -.--% | 50.04B | |
| 18.32x | 2.24x | 11.33x | 2.76% | 47.18B | |
| 32.2x | 6.38x | 21.65x | 0.62% | 46.61B | |
| 73.63x | 7.04x | 21.45x | -.--% | 41.32B | |
| 51.63x | 8.31x | 29.35x | -.--% | 38.56B | |
| Average | 33.94x | 6.46x | 20.59x | 0.48% | 83.08B | |
| Weighted average by Cap. | 36.39x | 6.80x | 21.28x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CTSO Stock
- Valuation Cytosorbents Corporation
Select your edition
All financial news and data tailored to specific country editions
